Johnson & Johnson (JNJ) Other Non-Current Liabilities (2009 - 2026)
Johnson & Johnson's (JNJ) quarterly Other Non-Current Liabilities came in at $10.1 billion in Q2 2026, up 773.03% year-over-year from $1.2 billion in Q2 2025, and down 1.05% quarter-over-quarter from $10.2 billion in Q1 2026.
Analysis
Johnson & Johnson (JNJ) Other Non-Current Liabilities (2009 - 2026) Analysis & Trends
Johnson & Johnson has disclosed Other Non-Current Liabilities across 18 years of filings, most recently posting $10.1 billion for Q2 2026.
- In Q2 2026, Other Non-Current Liabilities rose 773.03% year-over-year to $10.1 billion; the TTM figure through Jun 2026 stood at $10.1 billion (up 773.03% YoY), while the FY2025 annual figure was $9.9 billion, up 710.85% from the prior year.
- Other Non-Current Liabilities came in at $10.1 billion for Q2 2026 at Johnson & Johnson, down from $10.2 billion in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $10.2 billion in Q1 2026 to a low of $486.0 million in Q2 2022.
- Average Other Non-Current Liabilities over 5 years is $2.9 billion, with a median of $1.2 billion recorded in 2025.
- Year-over-year, Other Non-Current Liabilities retreated 19.0% in 2022 and soared 773.03% in 2026.
- Over 5 years, Other Non-Current Liabilities stood at $525.0 million in 2022, then surged by 108.0% to $1.1 billion in 2023, then gained by 11.45% to $1.2 billion in 2024, then jumped by 710.85% to $9.9 billion in 2025, then climbed by 2.36% to $10.1 billion in 2026.
- Per Business Quant data, the three most recent Other Non-Current Liabilities figures were $10.1 billion in Q2 2026, $10.2 billion in Q1 2026, and $9.9 billion in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 650.65 Bn | 629.89 Bn | 17.26 Bn |
| 2 | AbbVie | 466.34 Bn | 459.82 Bn | 12.70 Bn |
| 3 | Merck | 362.11 Bn | 355.02 Bn | 12.21 Bn |
| 4 | Novartis Ag | 267.81 Bn | 260.52 Bn | 11.24 Bn |
| 5 | Pfizer | 157.31 Bn | 145.91 Bn | 10.94 Bn |
| 6 | Bristol Myers Squibb | 128.75 Bn | 117.69 Bn | 9.25 Bn |
| 7 | Sanofi | 51.80 Bn | 44.84 Bn | 10.79 Bn |
| 8 | Revolution Medicines | 40.91 Bn | 40.91 Bn | - |
| 9 | BeOne Medicines | 39.65 Bn | 34.55 Bn | 1.53 Bn |
| 10 | Incyte | 25.18 Bn | 20.65 Bn | 1.57 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 28, 2026 | 10.10 Bn |
| Mar 29, 2026 | 10.21 Bn |
| Dec 28, 2025 | 9.87 Bn |
| Sep 28, 2025 | 9.93 Bn |
| Jun 29, 2025 | 1.16 Bn |
| Mar 30, 2025 | 1.23 Bn |
| Dec 29, 2024 | 1.22 Bn |
| Sep 29, 2024 | 1.22 Bn |
| Jun 30, 2024 | 1.25 Bn |
| Mar 31, 2024 | 1.11 Bn |
| Dec 31, 2023 | 1.09 Bn |
| Oct 1, 2023 | 1.18 Bn |
| Jul 2, 2023 | 1.14 Bn |
| Apr 2, 2023 | 1.14 Bn |
| Jan 1, 2023 | 1.12 Bn |
| Oct 2, 2022 | 525.00 Mn |
| Jul 3, 2022 | 536.00 Mn |
| Apr 3, 2022 | 486.00 Mn |
| Jan 2, 2022 | 533.00 Mn |
| Oct 3, 2021 | 613.00 Mn |